Immuneering CorporationIMRXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank35
3Y CAGR-58.2%
5Y CAGR-61.7%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-58.2%/yr
Quarterly compound
5Y CAGR
-61.7%/yr
Recent acceleration
Percentile
P35
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 0.52% |
| Q3 2025 | 4.44% |
| Q2 2025 | 7.24% |
| Q1 2025 | 11.67% |
| Q4 2024 | -10.63% |
| Q3 2024 | -5.64% |
| Q2 2024 | 3.35% |
| Q1 2024 | -3.51% |
| Q4 2023 | 10.25% |
| Q3 2023 | -1.17% |
| Q2 2023 | -10.64% |
| Q1 2023 | 6.67% |
| Q4 2022 | 7.06% |
| Q3 2022 | 8.11% |
| Q2 2022 | -10.22% |
| Q1 2022 | 25.51% |
| Q4 2021 | 21.15% |
| Q3 2021 | 93.96% |
| Q2 2021 | 13.18% |
| Q1 2021 | 4.06% |
| Q4 2020 | 62.83% |
| Q3 2020 | 11.02% |
| Q2 2020 | -2.26% |
| Q1 2020 | 0.00% |